Eosinophilic pneumonia in allergological practice


Cite item

Full Text

Abstract

In this article, current data on pulmonary eosinophilia are presented. Pulmonary eosinophilia is defined as the infiltration of eosinophils into the airways, interstitia, and alveoli. There are diverse processes in etiology, the common feature of which is the presence of pulmonary eosinophilic infiltrates, and as a rule, peripheral blood eosinophilia. Causes of pulmonary eosinophilia include various infections, medications, parasites, autoimmune processes, malignancies, and presence of obstructive pulmonary diseases. A unified classification of pulmonary eosinophilia is lacking, and instead, various versions of classifications have been presented. The most convenient classification option for use is also distinguished. This article discusses the historical transformation of the term “eosinophilic pneumonia” in the field of allergology, showing the lack of unambiguity in the concept of “eosinophilic pneumonia”, as well as the location of eosinophilic pneumonia in the pulmonary eosinophilia section. Eosinophilic pneumonia is defined as a disease characterized by an increase in the eosinophil content in the pulmonary tissue or bronchoalveolar lavage fluid. Most eosinophilic pneumonias are associated with peripheral blood eosinophilia. Two main variants of the disease are acute and chronic eosinophilic pneumonias. Thus, various ways to formulate diagnoses in various cases of eosinophilic pneumonia have been proposed.

About the authors

Sergey V. Tsarev

National Research Center – Institute of Immunology Federal Medical-Biological Agency of Russia

Author for correspondence.
Email: sv.tsarev@nrcii.ru
ORCID iD: 0000-0003-2235-243X
SPIN-code: 4590-9457
Scopus Author ID: 42462654000

MD, Dr. Sci. (Med.), Assistant professor

Russian Federation, 24, Kashirskoye shosse, Moscow, 115522

References

  1. Pytskiy VI, Adrianova NV, Artomasova AV. Allergic diseases. Series: Library of the practical doctor. The most important issues of internal medicine. Moscow: Meditsina; 1991. 368 p. (In Russ).
  2. Samsonova MV, Chernyaev AL. Eosinophilia of the lungs. Prakticheskaya pulmonologiya. 2016;(1):56–60. (In Russ).
  3. Rose DM, Hrncir DE. Primary eosinophilic lung diseases. Allergy Asthma Proc. 2013;34(1):19–25. doi: 10.2500/aap.2013.34.3628
  4. Crowe M, Robinson D, Sagar M, et al. Chronic eosinophilic pneumonia: clinical perspectives. Ther Clin Risk Manag. 2019;15:397–403. doi: 10.2147/TCRM.S157882
  5. Jeong YJ, Kim KI, Seo IJ, et al. Eosinophilic lung diseases: a clinical, radiologic, and pathologic overview. Radiographics. 2007;27(3):617–637. doi: 10.1148/rg.273065051
  6. Lоffler W. Zur differentialdiagnose der lungeninfiltrierungen II. Ueber fluchtige succedanininfiltrate (mit Eosinophilie). Beitr Klin Tuberk. 1932;79:368–382. doi: 10.1007/bf02079221
  7. Weingarten RJ. Tropical eosinophilia. Lancet. 1943;241:103–105. doi: 10.1016/s0140-6736(00)70615-5
  8. Cottin V. Diseases Elung. Eosinophilic lung diseases. Clin Chest Med. 2016;37(3):535–556. doi: 10.1016/j.ccm.2016.04.015
  9. Carrington CB, Addington WW, Goff AM, et al. Chronic eosinophilic pneumonia. N Engl J Med. 1969;280(15):787–798. doi: 10.1056/nejm196904102801501
  10. Leon-Kindberg M, Adida P, Rosenthal L. Pneumopathie et eosinophiles. Presse Med (Paris) 1940;48:277–278.
  11. To M, Kono Y, Yamawaki S, et al. A case of chronic eosinophilic pneumonia successfully treated with mepolizumab. J Allergy Clin Immunol Pract. 2018;6(5):1746–1748.e1. doi: 10.1016/j.jaip.2018.06.017
  12. Kaya H, Gümüş S, Uçar E. Omalizumab as a steroid-sparing agent in chronic eosinophilic pneumonia. Chest. 2012;142(2):513–516. doi: 10.1378/chest.11-1881
  13. Allen JN, Pacht ER, Gadek JE, Davis WB. Acute eosinophilic pneumonia as a reversible cause of noninfectious respiratory failure. N Engl J Med. 1989;321(9):569–574. doi: 10.1056/nejm198908313210903
  14. Badesch DB, King TE Jr, Schwarz MI. Acute eosinophilic pneumonia: a hypersensitivity phenomenon? Am Rev Respir Dis. 1989;139(1):249–252. doi: 10.1164/ajrccm/139.1.249
  15. Uchiyama H, Suda T, Nakamura Y, et al. Alterations in smoking habits are associated with acute eosinophilic pneumonia. Chest. 2008;133(5):1174–1180. doi: 10.1378/chest.07-2669
  16. De Giacomi F, Vassallo R, Yi ES, Ryu JH. Acute Eosinophilic Pneumonia. Causes, Diagnosis, and Management. Am J Respir Crit Care Med. 2018;197(6):728–736. doi: 10.1164/rccm.201710-1967CI
  17. Solomon J, Schwarz M. Drug-, toxin-, and radiation therapy-induced eosinophilic pneumonia. Semin Respir Crit Care Med. 2006;27:192–197. doi: 10.1055/s-2006-939522
  18. Bartal C, Sagy I, Barski L. Drug-induced eosinophilic pneumonia. Medicine. 2018;97(4):e9688. doi: 10.1097/MD.0000000000009688
  19. Jin F, Wang ST. Chronic eosinophilic pneumonia after trastuzumab and radiation therapy for breast cancer. Medicine. 2019;98(1):e14017. doi: 10.1097/MD.000000000001401
  20. Alonso RA, Zea-Mendoza AC, Salazar-Vallinas JM, et al. Toxic oil syndrome: a syndrome with features overlapping those of various forms of scleroderma. Semin Arthr Rheum. 1986;15(3):200–212. doi: 10.1016/0049-0172(86)90017-x
  21. Allen JA, Peterson A, Sufit R, et al. Post-epidemic eosinophilia-myalgia syndrome associated with L-tryptophan. Arthr Rheum. 2011;63(11):3633–3639. doi: 10.1002/art.30514
  22. Dallos T, Heiland G, Strehl J, et al. CCL17/thymus and activation-related chemokine in Churg-Strauss syndrome. Arthritis Rheum. 2010;62(11):3496–3503. doi: 10.1002/art.27678
  23. Wechsler ME, Akuthota P, Jayne D, et al. Mepolizumab or placebo for eosino philic granulomatosis with polyangiitis. N Engl J Med. 2017;376(20):1921–1932. doi: 10.1056/NEJMoa1702079
  24. Wechsler ME. Pulmonary eosinophilic syndromes. Immunol. Allergy Clin. North Am. 2007;27(3):477–492. doi: 10.1016/j.iac.2007.07.005

Supplementary files

Supplementary Files
Action
1. JATS XML

Copyright (c) 2021 Pharmarus Print Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies